In the treatment of pain, inflammation and fever, non-steroid anti-rheumatic drugs (NSAR) such as acetylsalicylic acid - more commonly known as Aspirin - or Ibuprofen have always been popular choices.
However, had they been tested using today's stringent criteria, many of these drugs would not have passed the clinical trial stage, due to the potential risks and side effects they entail. This suggests the need for more innovative thinking in this area of drug therapy. One such new approach has been developed in Manfred Schubert-Zsilavecz's laboratory at the Goethe University, using chemical substances belonging to the dual mPGES-1/5-LO-Inhibitors. Oliver Werz's group at Tübingen has characterized the substances at the molecular/pharmacological level. Their research results now form the basis of a joint patent application, and a publication in the renowned "Journal of Medicinal Chemistry" (Koeberle et al, J Med Chem (2008), Nov 19. [Epub ahead of print]).